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Abstract
Background: We describe drug-induced liver injury (DILI) secondary to antituberculous treatment (ATT) in a large
tuberculosis (TB) centre in London; we identify the proportion who had risk factors for DILI and the timing and
outcome of DILI.
Methods: We identified consecutive patients who developed DILI whilst on treatment for active TB; patients with
active TB without DILI were selected as controls. Comprehensive demographic and clinical data, management and
outcome were recorded.
Results: There were 105 (6.9%) cases of ATT-associated DILI amongst 1529 patients diagnosed with active TB
between April 2010 and May 2014. Risk factors for DILI were: low patient weight, HIV-1 co-infection, higher baseline
ALP, and alcohol intake. Only 25.7% of patients had British or American Thoracic Society defined criteria for liver test
(LT) monitoring. Half (53%) of the cases occurred within 2 weeks of starting ATT and 87.6% occurred within
8 weeks. Five (4.8%) of seven deaths were attributable to DILI.
Conclusions: Only a quarter of patients who developed DILI had British or American Thoracic Society defined
criteria for pre-emptive LT monitoring, suggesting that all patients on ATT should be considered for universal liver
monitoring particularly during the first 8 weeks of treatment.
Keywords: Tuberculosis, Drug induced liver injury, Hepatotoxicity, Re-introduction regimen, Risk factors, Liver failure
Background
Drug-induced liver injury (DILI) secondary to antituber-
culous treatment (ATT) is reported in 2–28% of patients
[1, 2] varying with the definition, study population and
treatment regimen. Risk factors associated with this po-
tentially fatal complication include co-infection with
HIV, hepatitis B or C, pre-existing chronic liver disease,
high alcohol intake, malnutrition, advanced age, female
sex and slow acetylators [1–11]. There is no agreed def-
inition of TB DILI and most definitions focus on ALT.
The DILI Expert Working Group have called for a con-
sensus on the threshold criteria for any drug-related
DILI, including ALT- and ALP-based criteria [12]. In
cases of suspected DILI it is important to assess causal-
ity, for example, using scoring systems such as the
Roussel Uclaf Causality Assessment Method (RUCAM)
score [[9].
ALP-based criteria may not be appropriate in TB,
given the granulomatous hepatitis picture associated
with the infection itself [13]. Transaminitis with ATT
may represent hepatic adaptation and occurs in up to
20% of patients receiving isoniazid monotherapy for la-
tent TB [14–16]. A balance must therefore be struck be-
tween unnecessary cessation of ATT and responding to
true DILI, given that the mortality of TB DILI can be up
to 27% [17, 18].
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Different recommendations have been made for moni-
toring liver tests (LTs) in patients on ATT by the British
Thoracic Society [19] the American Thoracic Society
(ATS) [14] and the European Respiratory Society (ERS)
[20] with some favouring a risk factor based approach.
Singanayagam et al. compared the two approaches, finding
in favour of universal testing 2 weeks into treatment [2].
The DILI Expert Working Group [12] and DILIGEN
study [21] use criteria based on ALT, ALP and bilirubin
to guide cessation of ATT. All expert recommendations
include treatment cessation at ALT > 5xULN or if the
patient is icteric; ATS recommends cessation if ALT is
3-5xULN and the patient reports symptoms including
nausea, anorexia, vomiting, abdominal pain and jaundice.
Each advisory body has recommendations for treatment
re-introduction when LTs have normalised; these either
advise sequential re-introduction with incremental dose
increase or re-introduction at full dosage [14, 19, 20].
Few UK studies have described LT monitoring for DILI,
criteria for diagnosis and DILI outcomes on ATT [2, 22].
We sought to determine the sensitivity of symptom screen
and risk factors in identifying DILI. In addition, we sought
to describe the biochemical and clinical characteristics,
clinical management and treatment outcomes for patients
who develop abnormal LTs on ATT at one of the largest
TB treatment centres in the UK.
Methods
Study design
We conducted a retrospective study of consecutive pa-
tients who developed DILI whilst on treatment for active
TB at Northwick Park Hospital between April 2010 and
May 2014. Patients with active TB were identified from
the London TB register (LTBR) and cases with DILI
were identified by case note review. For each patient
with DILI, two cases of active TB without DILI who
were treated during the same period (2011 to 2014) were
selected at random from the LTBR. These were patients
who had no abnormal LTs whilst on treatment. Patient
data were extracted from hospital electronic databases
and case records, including: demographic data, comor-
bidities, medications, symptoms, details of ATT, time of
DILI onset from start of ATT, and timing and nature of
reintroduction regimen. Risk factors investigated in-
cluded age, sex, baseline LTs, HIV, hepatitis B and C,
alcohol intake, chronic liver disease and drug dosage per
kg body mass. Ethics approval was not required as data
were collected routinely for clinical purposes.
Study population
This study was carried out in the TB centre of
Northwick Park Hospital, which is part of London North
West Healthcare (LNWH) NHS Trust. The Trust saw an
average of 600 TB patients annually from 2010 to 2014.
It is located in an ethnically diverse, urban area with a
low-to-medium prevalence of HIV, hepatitis B and C
infection.
Patient inclusion criteria and DILI definitions
We designated patients with a positive TB culture as
‘confirmed cases’ and those with negative culture with
clinical, histological and radiological features of TB and
who improved on treatment as ‘presumed cases.’
We identified and categorised possible DILI (pDILI)
cases any time after the start of ATT based on DILI ex-
pert working group [6] and DILIGEN criteria [15]. These
were as follows: type 1 - pDILI ALT >3xULN, type 2 -
pDILI ALP >2xULN and bilirubin >1xULN, and type 3
pDILI an isolated bilirubin >2xULN. We subdivided type
1 cases into patients with ALT >5xULN without symp-
toms (type 1a) and those with ALT 3-5xULN with symp-
toms (type 1b). In a risk factor analysis, DILI was
defined according to the BTS and ATS DILI guidelines
using the type 1a and type 1b definitions which are ALT
based; this was chosen due to ALP based criteria poten-
tially being affected by TB infection related cholestasis
and hence may not be indicative of true DILI [13]. At
the time of sampling, the ULNs in our laboratory were
ALT 55 IU/L, ALP 150 IU/L and bilirubin 21 umol/L.
No patients were excluded from the analysis.
Causality assessment
Other causes of liver injury were excluded with a viral
and autoimmune screen, an ultrasound of the liver and
the RUCAM score was calculated for each patient [9].
Monitoring and management of LTs during study period
Standard of care for the duration of the study was phys-
ician and TB nurse review at diagnosis with education
about ATT side-effects. Baseline LTs were performed
and all patients were offered HIV, hepatitis B and C
screening. The next physician review at two to 4 weeks
and at each subsequent visit included questioning about
symptoms of DILI: nausea, vomiting, abdominal pain,
dark urine, itching and loss of appetite. There was no
routine monitoring of LTs unless symptoms were
reported.
Patients with abnormal LTs were managed according
to local guidelines, which are based on BTS [19] and
ATS [14, 23] guidance. If the ALT was 3-5xULN with
symptoms or >5xULN without symptoms, ATT was
stopped or altered. Those with asymptomatic ALT 3-
5xULN either had their ATT altered or were monitored
closely depending on physician preference. In the event
of severe TB, we gave a non-hepatotoxic background
regimen (usually ethambutol plus amikacin) whilst
stopping rifampicin, isoniazid and pyrazinamide. LTs
were checked at intervals until ALT was normal or
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approaching normal. Treatment was re-introduced using
a staggered incremental dose increase regimen with
omission of pyrazinamide and consequential extension
of treatment to 9 months.
Details of re-introduction regimen
Re-introduction was as follows: day 1 onwards, normal
dose ethambutol plus: days 1–3 isoniazid 50 mg once
daily (OD); days 4 onwards, isoniazid 300 mg OD; plus:
days 7–9 rifampicin 75 mg OD; days 10–12 rifampicin
300 mg OD; day 13 onwards, normal doses of rifampi-
cin, isoniazid and ethambutol. LTs were monitored dur-
ing the re-introduction at days 0, 3, 6, 9, 12 and 15. We
did not re-introduce pyrazinamide, and treatment was
extended to 9 months for that reason.
Statistical analysis
Baseline characteristics of cases and controls were com-
pared using Fisher’s exact and Kruskal-Wallis tests. Lo-
gistic regression was used to estimate crude odds ratios
for each potential risk factor. Odds ratios were estimated
adjusted for age, sex and baseline levels of ALT, ALP
and bilirubin as a priori confounders. We investigated
whether peak ALT was associated with time from stop-
ping to reintroduction and with time from reintroduc-
tion to being established on full dose treatment, using
linear regression models adjusted for age, sex and base-
line ALT. All analyses were performed using Stata 13
(Stata Statistical Software: Release 13. StataCorp).
Results
We identified 105 (6.9%) cases of pDILI among 1529 pa-
tients diagnosed with confirmed or presumed TB be-
tween April 2010 and May 2014 (Fig. 1). Among the
pDILI cases, 92 (87.6%) had type 1 pDILI, one (0.1%)
had type 2 pDILI, and 12 (11.4%) had type 3 pDILI.
Seventy-seven of the pDILI cases fulfilled the ATS/BTS
criteria for TB DILI: 52 (49.5%) type 1a and 25 (23.8%)
had type 1b DILI.
RUCAM analysis
The RUCAM scores for causation of ATT are as follows:
all patients included scored 3 or above (possible relation-
ship to DILI). 45 (42.9%) had a score of 3–5 (possible,) 58
(55.2%) had a score of 6–8 (probable) and 2 (1.9%) had a
score of ≥9 highly probable. The median (IQR) of
RUCAM scale was 4 (4–6).
The characteristics of the pDILI cases are summarised
in Table 1. Initial treatment regimens are detailed in
Additional file 1: Table S1.
Symptoms
Seventy-one (67.6%) patients had the nature of their
symptoms recorded at the time of pDILI, the com-
monest being nausea and vomiting in 57 (54.3%), ab-
dominal pain in 19 (18.1%), skin complaints in 18
(17.1%) and clinical jaundice in 13 (12.4%) (Additional
file 1: Table S1).
Fig. 1 A flow chart showing the number of patients in the original cohort, those with possible DILI (pDILI) and those with DILI according to our
local guidelines which are based on BTS and ATS criteria; DILI 1a and DILI 1b were used for the risk factor analysis. ULN = Upper Limit of Normal.
ULN for ALT was 55 IU/L, for ALP 150 IU/L and for bilirubin 21umol/L
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Management and outcomes of pDILI
Median time to onset of pDILI was 12.5 (IQR: 7–30)
days (Fig. 2). Sixty-three (60%) patients stopped ATT; 11
of these received ethambutol and amikacin before re-
introduction. 11 (10.5%) stopped pyrazinamide only, of
whom five were given a quinolone (moxifloxacin or
levofloxacin) as a replacement for pyrazinamide, 27
(25.7%) patients did not stop treatment and four (3.8%)
had other interventions.
Full details of the management of the 63 patients who
stopped treatment are provided in Additional file 1:
Table S1.
The median time from stopping treatment to being
re-established on full-dose treatment was 28 days
(IQR 24–35): median time from stopping to starting
re-introduction was 18 days (IQR 14–28); from re-
introduction to being established on full-dose treat-
ment 14 days (IQR 9–22). Time from stopping to re-
introduction and time from re-introduction to being
established on full-dose treatment increased as peak
ALT increased: a mean increase of 7.1 (95% CI 1.0,
13.2) days (p = 0.02) per unit increase in log10 peak
ALT and 7.1 (95% CI 2.0, 12.3) days (p = 0.01) per
unit increase in log10 peak ALT (adjusted for age, sex
and baseline ALT).
Of the 27/105 (25.7%) patients who did not stop treat-
ment, seven had type 3 pDILI (bilirubin 41-54umol/L)
and ten had ALT 3-5xULN but no symptoms hence did
not meet the criteria for stopping treatment. These pa-
tients settled without intervention. Five patients had
ALT >5xULN and five had ALT 3-5xULN with symp-
toms. Of these ten, three had abnormal liver tests at
baseline which worsened then improved on treatment,
six were monitored more carefully and one met the cri-
teria for type 2 pDILI and settled with monitoring. In all
ten patients, pDILI settled; eight completed treatment
and two were lost to follow-up.
Of the 105 pDILI cases, 59 (56.2%) were successfully
re-established on treatment; 25 (23.8%) resolved without
stopping treatment, 13 (12.4%) had a second pDILI,
three (2.9%) were lost to follow up at time of DILI and
five (4.8%) died with liver injury as a probable contribut-
ing cause of death.
With regards to outcome of TB, 79 (75.2%) completed
treatment and were cured, seven (6.7%) died, two (1.9%)
discontinued treatment, ten (9.5%) transferred to an-
other centre and seven (6.7%) were lost to follow up
(Additional file 1: Table S1).
Of the 13 patients who had more than one episode of
pDILI, two had a history of alcohol excess, one had
hepatitis C and ten had no identified risk factors. Eight of
these recurrent pDILI cases completed TB treatment, two
died, one was transferred out to another centre and the
remaining two did not complete treatment as intended.
Table 1 Baseline characteristics of all cases of possible DILI (pDILI)
Characteristic n (%)
pDILI 105
Sex Female 49 (46.7)
Male 56 (53.3)
Age (years) 18–24 17 (16.2)
25–29 22 (21.0)
30–34 10 (9.5)
35–39 13 (12.4)
40–49 14 (13.3)
50–59 12 (11.4)
60+ 17 (16.2)
Ethnic origin Indian 55 (52.4)
Pakistani 8 (7.6)
Nepalese 8 (7.6)
Afghan 2 (1.9)
Somali 4 (3.8)
Romanian 2 (1.9)
Black 6 (5.7)
White 11 (10.5)
Asian (Other) 7 (6.7)
Other 2 (1.9)
Site of tuberculosis
Pulmonary 21 (20)
Extrapulmonary 61 (58.1)
Both 23 (21.9)
Total culture confirmed 62 (59)
Fully sensitive TB 56 (53.3)
Isoniazid monoresistant TB 3 (2.9)
Multi-drug resistant TB 3 (2.9)
HIV positive 8/96 (7.6)
HCV positive (detectable RNA) 3/98 (3.0)
HBV positive 0/101 (0)
Alcohol Excessa 9/105 (8.6)
Chronic Liver Diseaseb 7/105 (6.7)
No risk factorc 78/105 (74.2)
Other risk factors Median (IQR), n
Baseline ALT (IU/L) (normal range 10–50) 24 (17–32), n = 77
Baseline ALP (IU/L) (normal range 30–130) 98 (75–135), n = 77
Baseline BILI (umol/L) (normal range 0–21) 8 (6–12), n = 77
Weight (kg) 53.9 (48.0–65.0), n = 74
Rifampicin dose per kg (if given) 9.98 (9.00–11.1), n = 74
Isoniazid dose per kg (if given) 5.57 (4.62–6.25), n = 74
Pyrazinamide dose per kg (if given) 25.8 (22.7–29.8), n = 74
Moxifloxacin dose per kg (if given) 7.34 (6.15–8.15), n = 36
aAlcohol excess is defined as >21 units per week for men or >14 units per
week for women. bCauses of chronic liver disease are as follows: hepatitis C
(3), alcoholic liver disease (2), autoimmune hepatitis (1) and 1 drug related,
secondary to methotrexate. cAs defined by ATS/BTS
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Hospitalisations and deaths
There were 34 hospital admissions amongst 32 patients
(30% of total) with a median inpatient stay of 14 days
(IQR 7–21).
Of the seven (6.7%) deaths, the mean age was
55.1 years at diagnosis and mean baseline weight was
65.1 kg. One patient had HIV-1 co-infection, one had
myeloma, one had chronic renal failure, one had severe
emphysema, one was diabetic and had previous breast
cancer. Five of the seven were of South Asian origin.
None had a history of alcohol excess, chronic liver dis-
ease, hepatitis B or C, or were on other hepatotoxic
drugs. Three had pDILI within 2 weeks and one had re-
current pDILI; multiple attempts were made to restart
their treatment given the disseminated nature of their
TB. Two had pulmonary TB, three had extrapulmonary
TB and two had both. Five received standard quadruple
therapy, one had ethambutol substituted with moxifloxa-
cin due to renal failure and one received an undocu-
mented regimen. Two of the seven fatal cases reported
jaundice and had skin complaints at the time of their
pDILI and five reported no symptoms. One patient died
of liver failure whilst awaiting liver transplant; they were
42 years old and HIV-1 co-infected. The patient devel-
oped a widespread rash and a significant transaminitis
with a peak ALT of 1692 IU/L, a peak ALP of 509 IU/L
and a peak bilirubin of 148 umol/L (0–21). There was
also an eosinophilia and was diagnosed with DRESS syn-
drome. The other patients were considered but not re-
ferred for transplantation either because they did not
fulfil the criteria for liver transplantation or had absolute
or relative contraindications or significant comorbidities
that precluded transplantation; they received supportive
clinical care. Five of the seven died with pDILI being a
likely contributor to death giving an attributable mortal-
ity of 4.8%.
DILI risk factors
As previously described, 77 patients had ALT 3-5xULN
with symptoms or an ALT >5xULN, thereby meeting
ATS/BTS criteria for stopping TB therapy. There were
no baseline differences in sex, age or ethnicity between
DILI cases and controls. Baseline ALP was positively as-
sociated with a risk of DILI with an adjusted odds ratio
(AOR) 7.33 (95% CI 1.46–36.8) per 10-fold increase in
ALP, (p = 0.03) though median values for both groups
remained within the normal range (Table 2). Patient
weight was inversely associated with reduced risk of
DILI (AOR 0.96 (0.94–0.99) per kg, p = 0.003). Alcohol
intake (any amount) was associated with an increased
risk of DILI (AOR 5.94 (95% CI 2.34–15.1), p < 0.001).
Higher drug doses (per kg body weight) were associated
with an increased risk of DILI: isoniazid, AOR 1.77
(1.30–2.40) per 1 mg/kg increase in dose (p < 0.001);
pyrazinamide AOR 1.04 (1.00–1.09) per 1 mg/kg in-
crease in dose (p = 0.04). This dose-response effect was
not seen for rifampicin or moxifloxacin. The small num-
ber (eight) of HIV-1 co-infected patients had a four-fold
higher risk of DILI (AOR 4.40 (1.06–18.3), p 0.04)
(Tables 2 and 3). No positive association was found be-
tween increasing age and risk of DILI.
Discussion
Only 25.7% of patients who developed pDILI met BTS/
ATS criteria at baseline. At 6.9%, the rate of ATT-
associated pDILI in this cohort falls at the lower end of
Fig. 2 This bar chart shows the time to pDILI from the time of starting anti-TB treatment
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the estimates across different studies with rates reported
between 2% and 28% [1, 2, 8, 24–26], and is very similar
to a recent study from the UK that reports a rate of
7.3% [2]. More than half (53%) of pDILI occurred in the
first 2 weeks and 87% occurred within the first 2 months
of starting ATT. The duration of interruption of ATT in
patients with pDILI was related to peak ALT and there-
fore may be shortened by earlier identification of abnor-
mal LTs through universal rather than risk factor based
monitoring.
The definition of ATT-associated DILI at this centre
follows BTS and ATS guidance. The DILI expert work-
ing group [12] called for standardisation of DILI pheno-
types, including types based on ALP and bilirubin
criteria. This may not be appropriate for TB given that it
can cause a granulomatous hepatitis with raised ALP
[13], and a rising ALP on treatment may indicate a para-
doxical reaction rather than true DILI [12]. Of our six
cases with ALP >2xULN, three had an elevated ALP at
baseline; the ALP increased in all during treatment and
all except one had an associated ALT rise. Though it
may not be a useful marker in isolation, higher ALP at
baseline was an independent risk factor for DILI in our
study however it remained well within the normal range.
Isolated hyperbilirubinaemia does not fulfil the DILI
working group definition of DILI though BTS guidance
suggests monitoring and potentially stopping treatment
[19]. Some investigators report that hyperbilirubinaemia
is an independent predictor of mortality in patients with
DILI [17]. This is due to the fact that patients with sig-
nificant hepatocyte dysfunction may not produce an
ALT rise and hyperbilirubinaemia may be a late mani-
festation. In our cohort, seven of 12 patients who ful-
filled this definition had a bilirubin only slightly above
twice the ULN of bilirubin with a range between 41 and
54 umol/L. This was self-limiting and may reflect the ef-
fect of rifampicin.
In guidelines defining DILI, the ULN of ALT is often
not defined and there is high inter-laboratory variability
Table 2 Characteristics of pDILI Type 1 cases (BTS/ATS criteria) and controls
Characteristic Controls DILI cases
Median (IQR) Median (IQR) P-value†
Baseline ALT (IU/L) 19 (14–29), n = 185 24 (17–32), n = 77 0.03
Baseline ALP (IU/L) 86 (71–102), n = 187 98 (75–135), n = 77 0.03
Baseline bilirubin (umol/L) 8 (5–10), n = 185 8 (6–12), n = 77 0.28
Weight (kg) 61.2 (54.5–69.6), n = 178 53.9 (48.0–65.0), n = 74 0.001
Rifampicin dose per kg (if given) 9.68 (8.62–10.7), n = 178 9.98 (9.00–11.1), n = 74 0.17
Isoniazid dose per kg (if given) 4.85 (4.31–5.45), n = 178 5.57 (4.62–6.25), n = 74 <0.001
Pyrazinamide dose per kg (if given) 24.4 (21.4–27.5), n = 178 25.8 (22.7–29.8), n = 74 0.05
Moxifloxacin dose per kg (if given) 6.15 (5.71–7.04), n = 21 7.67 (5.71–8.00), n = 10 0.20
% (fraction) % (fraction)
HIV positive 2.2 (4/185) 7.3 (5/69) 0.06
HCV positive 1.7 (3/179) 1.4 (1/73) 1.00
HBV positive 2.2 (4/180) 0.0 (0/74) 0.33
Alcohol consumptiona Nil 93.3 (167/179) 71.4 (40/56) <0.001
Any 6.7 (12/179) 28.6 (16/56)
Chronic Liver Disease 2.2 (4/186) 3.9 (3/77) 0.42
† P-values from Kruskal-Wallis test (medians), Fisher’s exact test (proportions)
a Most patients drank no alcohol and only 1 patient (male) drank in excess of 21 units/week; given the small number of high alcohol intake, this was analysed as
no intake versus any intake of alcohol
Table 3 Odds ratios for exposures among pDILI Type 1 cases
compared with controls
Crude odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)a
Log baseline ALT (IU/L) 2.28 (0.96, 5.42) 1.96 (0.76, 5.04)
Log baseline ALP (IU/L) 6.67 (1.50, 29.7) 7.33 (1.46, 36.8)
Log baseline BILI (umol/L) 1.93 (0.56, 6.67) 2.20 (0.60, 8.01)
Weight (kg) 0.97 (0.95, 0.99) 0.96 (0.94, 0.99)
Rifampicin dose per kg 1.10 (0.93, 1.31) 1.12 (0.93, 1.35)
Isoniazid dose per kg 1.62 (1.22, 2.13) 1.77 (1.30, 2.40)
Pyrazinamide dose per kg 1.04 (1.00, 1.08) 1.04 (1.00, 1.09)
Moxifloxacin dose per kg 1.52 (0.83, 2.78) 1.53 (0.72, 3.27)
HIV 3.50 (0.91, 13.4) 4.40 (1.06, 18.3)
Alcohol Nil 1.00 (reference) 1.00 (reference)
Any 6.00 (2.59, 13.9) 5.94 (2.34, 15.1)
a Adjusted for age, sex and baseline ALT, ALP and bilirubin
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[14, 19, 27]. This variability can significantly alter esti-
mates of DILI and hamper understanding and manage-
ment of TB DILI [3, 27] as well as confounding
comparisons between centres. Values of ALT based on
weight and gender may be more useful.
Attribution of DILI to a particular medication can be
difficult; this is where scoring systems including
RUCAM are useful. In our study, all included patients
were scored as at least ‘possible’ and more than half of
the patients scored ‘probable’ relationship to DILI sec-
ondary to ATT. The RUCAM score takes into account
the time to onset of injury after starting the potentially
causative drug, course of DILI after stopping the drug,
specific risk factors, other medications which can cause
DILI, exclusion of other causes of liver disease, known
potential for DILI of the drug in question and response
to rechallenge [9, 10, 28]. In ATT related DILI the lack
of response to rechallenge may not be against the causa-
tive role of ATT as rechallenge can be successful [1, 12]
and is advised by some experts [9, 14, 19].
The commonest symptoms our DILI patients reported
were nausea and vomiting, affecting 54.3%. Gastric
intolerance frequently occurs with ATT, especially
pyrazinamide, however we advise a low threshold for
LTs in patients with these complaints. Jaundice was
lower (12.4%) among our patients than in other cen-
tres [17, 29, 30] who reported a higher mortality pos-
sibly reflecting earlier diagnosis in our cohort.
There is no clear evidence as to whether staggered re-
introduction with incremental dose increase, or restart-
ing drugs at full dose, is preferable [14, 19, 31–34]. In-
cremental dose increase results in longer without full
treatment, but may be safer and allow for hepatic adap-
tation. Among our pDILI patients, the median time from
stopping treatment to re-establishment on full dose ATT
was 28 days (IQR 24–35), a significant interruption in
treatment. The duration of interruption was related to
the peak ALT and therefore may be shortened by earlier
identification of DILI. 75.2% of our patients successfully
completed a regimen containing at least RHE; others re-
port higher completion rates [35] though differences in
DILI definition [1, 12, 14, 19] and patients lost to follow
up or transferred to other centres mean our completion
rate may be higher.
We found that HIV co-infection, lower weight, alcohol
intake and higher baseline ALP were associated with in-
creased risk of DILI; other risk factors were not associ-
ated with DILI. Most notably, increasing age was not
found to be a risk factor which is consistent with other
studies [5, 8]. This may be because only 16.2% of cases
were over 65 years of age and because older patients are
considered at high risk for DILI, we often omitted pyra-
zinamide in these patients and monitored them more
carefully for side effects [14]. Alcohol excess has been
reported as a risk factor in other studies however in our
study, we report alcohol intake as a risk factor given the
low occurrence of alcohol excess in our cohort [1, 14, 36].
Given that 74.3% of patients did not meet ATS/BTS
criteria, we agree with Singanayagam et al. that tar-
geted monitoring of DILI in those with these risk fac-
tors is an insensitive strategy and can result in delayed
diagnosis [2].
In our study, 53% of pDILI occurred within 2 weeks
and 87% by 2 months. The median time to pDILI of
12.5 days (CI 7–30) is comparable with other reports
[2, 24, 25] and indicates to us that all patients should
have LTs 2 weeks after starting ATT, even if asymp-
tomatic. Given the frequency of ATT-associated DILI,
regular monitoring of LTs in the first 2 months of
treatment would capture the vast majority of cases as
is recommended for other hepatotoxic drugs such as
DMARDs (disease modifying anti-rheumatic drugs.) [37].
Recently published 2016 NICE guidelines do not have
clear guidance on the monitoring of LTs to detect hep-
atotoxicity in patients with active TB [38], although they
do have recommendations for the sequential, full-dose
re-introduction of ATT in those who have a treatment
interruption due to hepatotoxicity.
Limitations of this study include its retrospective na-
ture, meaning that monitoring for occurrence of pDILI
could have varied over time, though this is unlikely given
that the TB specialists managing patients remained the
same during this period. It would also have contributed
to incomplete recording of symptoms. Rates of pDILI
could be higher given the possibility of asymptomatic
pDILI; those patients could be identified if there was
universal LT testing of all patients regardless of symp-
toms. Although our definitions of ATT-associated DILI
followed BTS and ATS guidance, it is possible that some
DILI cases may not be attributable to ATT. Ideally, a
replication study would have a multi-centre, prospective
design and use the RUCAM scale as part of the assess-
ment of causality. Our study describes data from a single
centre, and would benefit from replication. However, this
is a large study, is representative of the UK TB cohort
and is one of the few recent UK-based studies that pro-
vides relevant data which characterises DILI in the UK.
Conclusions
In this study, we demonstrate an overall pDILI rate
of 6.9% in this cohort and mortality with pDILI as a
contributor in 4.8%. We have not found a risk factor
screen approach useful with only 25.7% meeting this
criteria. Though there are short comings, this study
indicates that monitoring of LTs during the first 2
months of ATT should identify the majority of pDILI
earlier, possibly shortening treatment interruption and
reducing mortality.
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